#vm202

VM202 is a Safe, Beneficial Treatment for Limb Ischemia

The Korean biotechnology company ViroMed Co., Ltd. has announced the publication of a Phase 2 study that evaluated their VM202 product in patients with critical limb ischemia. This study involved 52 patients in the United States and showed that VM202 is not only safe, but also produced significant clinical benefits. VM202 is a plasmid (small circle of DNA) that encodes the human hepatic growth…